Robyn Karnauskas
Stock Analyst at Truist Securities
(1.92)
# 3,177
Out of 5,124 analysts
178
Total ratings
43.79%
Success rate
-0.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Buy | $1,038 → $1,182 | $1,080.36 | +9.41% | 6 | Nov 19, 2025 | |
| ABCL AbCellera Biologics | Maintains: Buy | $28 → $10 | $3.43 | +191.55% | 2 | May 16, 2025 | |
| AMGN Amgen | Maintains: Hold | $333 → $298 | $327.64 | -9.05% | 12 | Jan 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $65 | $53.46 | +21.59% | 2 | Jan 8, 2025 | |
| MRK Merck & Co. | Downgrades: Hold | $130 → $110 | $106.45 | +3.33% | 11 | Jan 8, 2025 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $121.60 | -31.74% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $229.31 | -8.42% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $1.34 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $177.82 | +91.20% | 17 | May 16, 2024 | |
| CRIS Curis | Maintains: Buy | $26 | $0.98 | +2,544.96% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $1.37 | +410.95% | 13 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,135 | $776.31 | +46.20% | 16 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $1.88 | +431.91% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $3.61 | +149.31% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $21.93 | +4.88% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $25.91 | +85.26% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $23.29 | +114.68% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $452.13 | +12.36% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $25.18 | +42.97% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $76.74 | -67.42% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.70 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $59.45 | +135.49% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30,000 | $3.64 | +824,075.82% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $0.99 | +609.65% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $23.39 | +135.14% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $11.27 | +2,739.40% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $26.02 | -42.35% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $85 | $0.10 | +82,665.34% | 1 | Oct 8, 2020 |
Eli Lilly and Company
Nov 19, 2025
Maintains: Buy
Price Target: $1,038 → $1,182
Current: $1,080.36
Upside: +9.41%
AbCellera Biologics
May 16, 2025
Maintains: Buy
Price Target: $28 → $10
Current: $3.43
Upside: +191.55%
Amgen
Jan 8, 2025
Maintains: Hold
Price Target: $333 → $298
Current: $327.64
Upside: -9.05%
Bristol-Myers Squibb Company
Jan 8, 2025
Maintains: Buy
Price Target: $62 → $65
Current: $53.46
Upside: +21.59%
Merck & Co.
Jan 8, 2025
Downgrades: Hold
Price Target: $130 → $110
Current: $106.45
Upside: +3.33%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $121.60
Upside: -31.74%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $229.31
Upside: -8.42%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.34
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $177.82
Upside: +91.20%
Curis
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $0.98
Upside: +2,544.96%
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $1.37
Upside: +410.95%
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $776.31
Upside: +46.20%
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $1.88
Upside: +431.91%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $3.61
Upside: +149.31%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $21.93
Upside: +4.88%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $25.91
Upside: +85.26%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $23.29
Upside: +114.68%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $452.13
Upside: +12.36%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $25.18
Upside: +42.97%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $76.74
Upside: -67.42%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.70
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $59.45
Upside: +135.49%
Sep 6, 2023
Reiterates: Buy
Price Target: $30,000
Current: $3.64
Upside: +824,075.82%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $0.99
Upside: +609.65%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $23.39
Upside: +135.14%
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $11.27
Upside: +2,739.40%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $26.02
Upside: -42.35%
Oct 8, 2020
Initiates: Buy
Price Target: $85
Current: $0.10
Upside: +82,665.34%